Several JAK inhibitors, as a mode of indirect STAT inhibition, do have EMA and FDA approval but mainly for the treatment of rheumatoid arthritis, in addition to myeloproliferative neoplasms. The gene discussed is SOAT1; the disease is myeloproliferative disorder.